MTF Biologics, Kolosis BIO Partner to Launch Summit Matrix™ in Orthopedic and Spine Care
Published: 21 Jan 2026
Author: Precedence Research
MTF Biologics, a nonprofit organization based in the U.S. focused on advancing tissue and organ transplantation, donation, and research, has announced the release of Summit Matrixtm, an improved type of synthetic bone graft development, by partnering with an orthobiologics specialist, Kolosis BIO. As part of extending the bone regenerative solutions proposed following orthopedic and spinal surgeries.
Summit Matrix is a new generation of synthetic graft solutions that integrate biomimetic material science with surgeon-friendly usability. The NanoLifttm surface technology that the product is operated by combines the nanoscale topography and nanoscale chemistry to create superior biological performance with outstanding handling properties in the operating room.
Summit Matrix is a major advance in osteobiologic solutions that develop around NanoLifttm nanocrystalline. They have a plate-like surface architecture that is developed to support cellular attachment and activity that are essential for bone regeneration. It is composed of hydroxycarbanoapatite, a biomimetic material analogous to natural bone mineral, which allows for maximum resorption and osseointegration over time. This stability/biological integration balance is critical in more complicated orthopedic and spinal surgery. Furthermore, the Summit Matrix will likely have a significant role in determining the future of synthetic bone grafting as it will help to bridge the gap between biologic performance and the practicality of the surgery.
Executives’ Statements
Brad Bailey, Vice President and General Manager of MTF Biologics’ Orthopedic Franchise, stated, “MTF Biologics was founded by orthopedic surgeons nearly 40 years ago with a mission to provide solutions that genuinely improve patient care. Summit Matrix continues this legacy by representing a meaningful leap forward in synthetic bone graft technology. Our expanded collaboration with Kolosis BIO allows us to deliver innovations that enhance surgical efficiency while supporting strong clinical outcomes.”
Collin Begley, Chief Executive Officer of Kolosis BIO, commented, “Kolosis has emerged as a leading pure-play orthobiologics provider in spine and orthopedics, and the addition of Summit Matrix significantly strengthens our portfolio. This technology is well-positioned to make an immediate impact in the market, and our partnership with MTF Biologics enables us to offer surgeons a best-in-class combination of allograft tissues and advanced synthetic ceramics through a single trusted partner.”